Arca
Skip to content
Tools
Tools

Lupus nephritis

Drug research and approvals for lupus nephritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 87 studies of lupus nephritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 87
  • Trials authorized in Canada: 15
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 87 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

  • VoclosporinSerine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
  • BelimumabTumor necrosis factor ligand superfamily member 13B inhibitor

Phase 3 12 of 18

Phase 2 12 of 24

Phase 1 or earlier 5

How its trials ended

255 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 60 whose ending is known, 25% met their primary endpoint, 8% missed it and 67% stopped early.

  • Ongoing8935%
  • Completed, result not reported6224%
  • Status unknown4417%
  • Stopped: other or unclear187%
  • Met its primary endpoint156%
  • Stopped: enrollment or feasibility73%
  • Stopped: sponsor or business decision62%
  • Missed its primary endpoint52%
  • Stopped: lack of efficacy52%
  • Stopped: safety31%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 15; search them all in Canada trials
May 14, 2025A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate efficacy, safety, pharmacokinetics (PK) and…Ianalumab (VAY736)Novartis PharmaceuticalsPending
Dec 17, 2024A phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus…YTB323 (rapcabtagene autoleucel) / Fludarabine phosphate / CyclophosphamideNovartis PharmaceuticalsPending
Nov 9, 2023An open label phase 1b study of felzartamab in lupus nephritisFelzartamab (HIB202)Human Immunology Biosciences, Inc. (Hi-Bio)Ongoing
Dec 12, 2022A phase 3 randomized, double-blind, placebo-controlled multicenter, multinational study to evaluate the efficacy and safety of atacicept in subjects with…Atacicept (VT-001) / Mycophenolate mofetilVera TherapeuticsPending
May 6, 2022A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top…VAY736 / Cellcept / MyforticNovartis PharmaceuticalsOngoing
Aug 6, 2021A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab in…Gazyva / MyfenaxRocheOngoing
Jan 27, 2021A phase 2 randomized, double-blind, multicenter study to evaluate the safety and efficacy of oral rilzabrutinib compared to placebo in adult patients with…Rilzabrutinib (PRN1008) / MycophenolatePrincipia BiopharmaPending
Dec 11, 2020A phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with proliferative lupus…RavulizumabAstraZeneca PharmaceuticalsOngoing
May 15, 2020A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of obinutuzumab in patients with isn/rps 2003…Gazyva (obinutuzumab) / Myfenax (mycophenolate mofetil)RocheClosed
Apr 1, 2020A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c.…CosentyxNovartis PharmaceuticalsClosed

FDA orphan designations

Approved first, then open designations, newest first
Jul 28, 2000AbetimusTreatment of lupus nephritis.La Jolla Pharmaceutical Co.Designated
Feb 3, 1998BindaritTreatment of lupus nephritis.Angelini Pharmaceuticals, Inc.Designated
Jan 7, 1993Monoclonal antibody for immunization against lupus nephritisTreatment of lupus nephritis.VivoRx Autoimmune, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 15, 2022LupkynisVoclosporinOtsuka Pharmaceutical Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.